Edwards Lifesciences

Abbott initiates real-world TriClip postmarket study as Edwards prepares Pascal U.S. launch

Abbott begins a 1,000-patient postmarket study of its TriClip tricuspid repair device, gathering real-world safety and efficacy data ahead of anticipated U.S. competition from Edwards Lifesciences.